| Autor: |
Gilbert, J., Ketchen, M., Kane, P., Mason, T., Baister, E., Monaghan, M., Barr, S., Harris, P.E. |
| Zdroj: |
Pituitary; Mar2003, Vol. 6 Issue 1, p11-18, 8p |
| Abstrakt: |
Aim: Somatostatin analogues are normally used as adjunctive therapy to surgery and radiotherapy in management of acromegaly. We studied the effects of de novo OCT-LAR treatment on growth hormone (GH) suppression, tumour size, cardiovascular function, clinical symptoms, signs and quality of life in 9 newly diagnosed acromegalic patients. Methods: Patients commenced OCT-LAR 20 mg IM monthly for 2 months. Dose increased to 30 mg monthly if mean serum GH (MGH) >5 mU/l (2 μg/litre) (7 patients). Treatment continued for 6 months. Cardiac function assessed by echocardiography at baseline and day 169. Left ventricular (LV) mass and ejection fraction (EF) calculated from 2D M-mode studies. Results: Serum GH demonstrated suppression in 8/9 patients (mean suppression 64.9% ± 29.7%, range; 4–95.2%). MGH suppressed <5 mU/l (2 μg/litre) in 3 (33%) patients. IGF-I and IGFBP3 normalised in 1 (12.5%) and 3 (38%) patients respectively. Tumour shrinkage seen in 30% patients. Eight patients were assessed by echocardiography. At baseline, 7 patients demonstrated abnormalities in LV mass and EF. At day 169, 6 patients demonstrated a fall and 1 an increase in LV mass. Overall there was no significant change in LV mass. A significant increase in EF was observed ( p = 0.02). There were significant improvements in health perception ( p = 0.01), fatigue ( p < 0.05) and perspiration ( p = 0.0039). Conclusions: These data demonstrate OCT-LAR provides adequate control of acromegaly in a proportion of patients treated over 6 months. This is associated with improved LV function, evidenced by increased EF. Improved results are expected with longer-term treatment. OCT-LAR may be considered as primary treatment for acromegaly in selected patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink